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Objective: To evaluate the antimicrobial susceptibility of Gram-negative uropathogens isolated from pregnant
women.
Methods: We performed a snapshot cohort study of women receiving care in the University of Florida prenatal
clinics duringMarch2000. Subjects with asymptomatic bacteriuria or cystitis were identified and the antimicrobial
susceptibility of each pathogen was recorded. Data were analyzed using chi-square, Fisher’s exact test and
ninety-five percent confidence intervals, as appropriate.
Results: Ninety-five positive cultures were identified. Isolates were more often susceptible to trimethoprim-
sulfamethoxazole (TMP-SMX)(87%)andnitrofurantoin(89%)thantoampicillin (72%)(p < 0.03).Escherichiacoli
accountedfor 71 (75%) cases and was more often susceptibleto nitrofurantoin(100%) than to TMP-SMX (87%)
(p < 0.01). Proteus isolates were all susceptible to TMP-SMX and resistant to nitrofurantoin (p < 0.01).
Conclusions: Both TMP-SMX and nitrofurantoinare superiorto ampicillin for empiric treatment of lower urinary
tract infection in pregnant women. Nitrofurantoin is superior to TMP-SMX for treatment of infections caused by
E. coli. For suspected or confirmed cases caused by Proteus organisms, TMP-SMX is the preferred agent.
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Urinary tract infections (UTI) are the most
commonly encountered infections in obstetric
patients1. These infections can be divided into
asymptomatic bacteriuria (ASB), occurring in
5–10% of patients; acute cystitis, affecting 1–3% of
patients; and pyelonephritis, which complicates
0.5–1.5% of pregnancies2. Most cases of
pyelonephritis are the sequelae of untreated,
recurrent or inadequately treated lower UTI.
Pyelonephritis is the most common non-obstetric
cause of hospital admission during pregnancy and
can lead to preterm labor, maternal sepsis and
acquired respiratory distress syndrome (ARDS)3.
Pregnant women diagnosed with ASB or acute
cystitis are often treated empirically before the
results of culture and sensitivity testing are
available4. The choice of empiric antibiotic
therapy should be based on established patterns of
antimicrobial sensitivities in the specific institu-
tion.In thepast, ampicillin was used extensively as
first-line treatment. However, in recent years, the
usefulness of ampicillin has been limited because
of the growingemergence of bacterial strains resis-
tant to this antibiotic5. Currently, the two most
commonly chosen therapies are trimethoprim-
sulfamethoxazole(TMP-SMX)andnitrofurantoin
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Clinical study 123monohydrate macrocrystals (hereafter referred to
as nitrofurantoin)6.
At the University of Florida, TMP-SMX has
beentheagentofchoiceduetolowercostandpre-
sumed equal efficacy. Unpublished data from our
institution showed that as recently as 1996 the
resistance of common uropathogens to TMP-
SMX and nitrofurantoin was equal. However, the
cost difference has been narrowing and, more
importantly, recent reports suggest there may
be increasing resistance to TMP-SMX among
common uropathogens7–10. As an example,
researchers from the University of Washington
recently reported that the resistance of Escherichia
coli in healthy, nonpregnant women to
TMP-SMX increased from 9% to 18% from
1992 to 19967. The same investigators also
reported that resistance of E. coli to nitrofurantoin
during the same time period was only 0.2% and
did not change over time7.
We undertook this study to evaluate which
agent should be used for empiric therapy of lower
UTI in our obstetric population. The objective of
our investigation was to determine the frequency
of resistance of common uropathogens to
ampicillin, TMP-SMX and nitrofurantoin.
SUBJECTS AND METHODS
We performed a snapshot cohort study by system-
atically reviewing all of the prenatal charts in the
University of Florida clinic system during March
2000. Therefore, this cohort represents patients at
variousgestational ageswhowere receiving care in
the system at that time. All cultures from the
current pregnancy were included in the review.
The investigation was approved by the University
of Florida Health Center Institutional Review
Board. We removed all patient identifiers from
our records once data had been abstracted from
subjects’ charts.
More than 90% of our patients are indigent,
either uninsured or insured by the Medicaid
program and most live in rural areas around
Gainesville. Approximately 80% of patients
are Caucasian and most of the remainder are
African-American. The vast majority of these
patients received prenatal care in the rural county
health departments or in the residents’ continuity
clinics. Approximately 5% of subjects received
care in the faculty private practice.
Patients with a diagnosis of ASB or cystitis were
identified. For the purpose of this investigation,
asymptomatic bacteriuria was defined as a clean-
catch midstream urine culture showing greater
than 100 000 colonies per milliliter (CPM) of a
single Gram-negative uropathogenduring routine
prenatal screening in an asymptomatic patient.
Cystitis was diagnosed in women who had symp-
toms of frequency, urgency or hesitancy and a
urine culture that had greater than 100 000 CPM
of a single Gram-negative organism. The type of
infection (ASB or cystitis), causative organism and
antibiotic sensitivity profile were recorded for
each positive culture. The antibiotics specifically
evaluated were ampicillin, TMP-SMX and
nitrofurantoin.
Resultswereanalyzedwithdescriptivestatistics.
The uncorrected chi-square test and Fisher’s exact
test were applied for categorical variables.
Ninety-five percent confidence intervals were
used for proportions. All statistical tests were two-
tailed and we considered a p-value of < 0.05 to
be statistically significant.
RESULTS
A total of 95 pregnant women with positive urine
culturesmeeting theinclusion criteria were identi-
fied. Of these women, 72 had ASB and 23 had
cystitis. E. coli was isolated from 71 (75%) subjects.
Klebsiella pneumoniae and Proteus mirabilis
accounted for eight (8%) cases each. The remain-
ing cultures were positive for Pseudomonas (two
cases), Citrobacter (three cases) and Acinetobacter
(three cases).
Table 1 presents the proportionsof isolates that
were susceptible to ampicillin, TMP-SMX and
nitrofurantoin. When considering all Gram-
negative organisms combined, susceptibility to
TMP-SMX and nitrofurantoin were similar
(p = 0.65).Bacterial isolates were more likely tobe
susceptible to either of these agents than to
ampicillin (p < 0.03 for TMP-SMX and p < 0.01
for nitrofurantoin). When considering only infec-
tions caused by E. coli, significantly more of the
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to TMP-SMX (p < 0.03). Klebsiella isolates were
equally as likely to be susceptible to TMP-SMX as
to nitrofurantoin. All of the Proteus isolates were
susceptible to ampicillin and TMP-SMX; none
were susceptible to nitrofurantoin(p < 0.01). The
distribution of bacteria recovered from women
with ASB was no different from that recovered
from women with acute cystitis.
DISCUSSION
The results of our investigation confirm earlier
studies that demonstrate that the resistance rate of
uropathogensto ampicillin is high enough to pre-
vent this drugfrombeing acceptableempiric treat-
ment for lower UTI in pregnancy. We also have
shown that, in our population, TMP-SMX and
nitrofurantoinare bothstill effective against almost
90% of common uropathogens.
For the most common uropathogen, E. coli,
nitrofurantoin is superior to TMP-SMX: in our
study sample, 100% of E. coliisolates were suscept-
ible to nitrofurantoin. Prior studies have also
shown a sensitivity rate of 95–100%7,10. Because
75–90% of simple UTI in young women are
caused by E. coli11, our clinical guidelines now
recommend using nitrofurantoin as empiric
therapy for uncomplicated lower UTI in
pregnancy.
Nitrofurantoin would be a poor choice if a
Proteus infection were suspected. Factors that
might raise one’s clinical suspicion that a given
patient was infected with a strain of Proteus would
include a history of oxalate nephrolithiasis, recur-
rent UTI, chronic instrumentation or indwelling
catheters, or immunodeficiency. In addition,
Proteus species contain urease, an enzyme that
releases ammonia and causes the urinary pH to be
alkaline. The ability of urinary pH to predict the
causal pathogenincases oflowerUTIhas notbeen
evaluated. However, nitrofurantoin might not be
the best choice for empiric therapy if the urinary
pH is high.
In this investigation, we used in vitro antibiotic
susceptibility of isolated urinary pathogens as the
primary outcome. Clearly, the outcome that is
more important is clinical response to therapy.
However, our study only adds to a growing body
of evidence that the proportion of uropathogens
resistant to TMP-SMX is increasing7–10. In addi-
tion, the fact that nitrofurantoin works through
multiple mechanisms of action reduces the likeli-
hood that bacteria will develop resistance to this
antibiotic12. Considered collectively, these facts,
along with the fact that the cost of nitrofurantoin
and TMP-SMX are currently more comparable
than in the past, we think that nitrofurantoin is
the preferred agent for empiric therapy of lower
UTI in pregnant women.
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100% (68,100)
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100% (95, 100)*
75% (41, 93)
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89% (81, 94)+
*p < 0.01 for TMP-SMX versus nitrofurantoin;
+p = 0.65 for TMP-SMX versus nitrofurantoin, but p < 0.03 for TMP-SMX versus ampicillin
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